Mayo Clinic's approach

Mayo Clinic's CAR-T Cell Therapy Program is one of a few such programs at select medical centers with experts trained and certified to manage this innovative cancer treatment.

Your Mayo Clinic care team

To ensure that you have access to the latest treatments possible, Mayo Clinic hematology experts conduct research at the leading edge of science. Our researchers intensively study the causes and mechanisms of blood diseases and develop novel treatments to cure these diseases.

Your care is directed by a team made up of doctors and other healthcare professionals who work together to provide you with the best care. CAR-T Cell Therapy Program doctors and other specialists consult with their colleagues about your condition and recommend treatment options based on their experience and evidence-based medicine. Mayo Clinic's experts have treated people in the landmark clinical trial that led to FDA approval of this innovative therapy.

If you're considering CAR-T cell therapy, your care team might include:

Expertise and rankings

Mayo Clinic doctors are widely respected for their expertise in using innovative treatments, such as CAR-T cell therapy for advanced blood cancers. When you seek care at Mayo Clinic, you can expect:

  • Personalized care. At Mayo Clinic, an expert team of hematologists, medical oncologists, radiation oncologists, pathologists and other specialists, if needed, work together to give you exactly the care you need.
  • Experience you can trust. Mayo Clinic doctors are respected for their experience in caring for people with different blood cancers and for using innovative treatments for  cancer and other conditions.
  • Nationally recognized expertise. Mayo Clinic Comprehensive Cancer Center meets the strict standards for a National Cancer Institute-designated comprehensive cancer center. These standards recognize scientific excellence and a multispecialty approach focused on cancer prevention, diagnosis and treatment.
  • Ongoing research. Mayo Clinic researchers are continuously looking at new ways to treat blood cancers and ways to improve existing treatments. They are engaged in multiple clinical trials surrounding CAR-T cell therapy. They're also looking for ways to extend their knowledge and experience of CAR-T cell therapy to other kinds of cancers, including solid tumors.

Mayo Clinic in Rochester, Minnesota, Mayo Clinic in Jacksonville, Florida, and Mayo Clinic in Phoenix/Scottsdale, Arizona, are ranked among the Best Hospitals for cancer by U.S. News & World Report. Mayo Clinic in Rochester, Minnesota, is ranked as the top hospital in Minnesota, Mayo Clinic in Phoenix/Scottsdale, Arizona, is ranked as the top hospital in Arizona, and Mayo Clinic in Jacksonville, Florida, is ranked the top hospital in Florida.

Locations, travel and lodging

Mayo Clinic has major campuses in Phoenix and Scottsdale, Arizona; Jacksonville, Florida; and Rochester, Minnesota. The Mayo Clinic Health System has dozens of locations in several states.

For more information on visiting Mayo Clinic, choose your location below:

Costs and insurance

Mayo Clinic works with hundreds of insurance companies and is an in-network provider for millions of people.

In most cases, Mayo Clinic doesn't require a physician referral. Some insurers require referrals or may have additional requirements for certain medical care. All appointments are prioritized on the basis of medical need.

Learn more about appointments at Mayo Clinic.

Please contact your insurance company to verify medical coverage and to obtain any needed authorization prior to your visit. Often, your insurer's customer service number is printed on the back of your insurance card.

More information about billing and insurance:

Mayo Clinic in Arizona, Florida and Minnesota

Mayo Clinic Health System

June 27, 2025
  1. Brudno JN, et al. CAR T cells and T-cell therapies for cancer. JAMA. 2024; doi:10.1001/jama.2024.19462.
  2. CAR T cells: Engineering patients' immune cells to treat their cancers. National Cancer Institute. https://www.cancer.gov/about-cancer/treatment/research/car-t-cells. Accessed April 16, 2025.
  3. Kymriah (prescribing information). Novartis; 2024. https://us.kymriah.com. Accessed April 24, 2025.
  4. Yescarta (prescribing information). Kite Pharma; 2024. https://www.yescartahcp.com. Accessed April 24, 2025.
  5. Tecartus (prescribing information). Kite Pharma; 2024. https://www.tecartushcp.com. Accessed April 24, 2025.
  6. Breyanzi (prescribing information). Bristol Myers Squibb; 2024. https://www.breyanzihcp.com. Accessed April 24, 2025.
  7. Abecma (prescribing information). Bristol Myers Squibb; 2024. https://www.abecma.com/. Accessed April 24, 2025.
  8. Carvykti (prescribing information). Janssen Biotech; 2024. https://www.carvykti.com. Accessed April 24, 2025.
  9. Aucatzyl (prescribing information). Autolus; 2024. https://www.autolus.com. Accessed April 24, 2025.
  10. Roddie C, et al. Obecabtagene autoleucel in adults with B-cell acute lymphoblastic leukemia. New England Journal of Medicine. 2024; doi:10.1056/NEJMoa2406526.
  11. Immunotherapy side effects: CAR T-cell therapy. National Comprehensive Cancer Network. http://www.NCCN.org/patientguidelines. Accessed April 16, 2025.
  12. Hines MR, et al. Immune effector cell-associated hemophagocytic lymphohistiocytosis-like syndrome. Transplantation and Cellular Therapy. 2023; doi:10.1016/j.jtct.2023.03.006.
  13. Amini L, et al. Preparing for CAR T cell therapy: Patient selection, bridging therapies and lymphodepletion. Nature Reviews: Clinical Oncology. 2022; doi:10.1038/ s41571-022-00607-3.
  14. Steinbach M, et al. Nursing care throughout the chimeric antigen receptor T-cell therapy process for multiple myeloma. Seminars in Oncology Nursing. 2023; doi:10.1016/j.soncn.2023.151505.
  15. Acute lymphoblastic leukemia. National Comprehensive Cancer Network. https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1410. Accessed April 22, 2025.
  16. B-cell lymphomas. National Comprehensive Cancer Network. https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1480. Accessed April 22, 2025.
  17. Chronic lymphocytic leukemia. National Comprehensive Cancer Network. https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1478. Accessed April 22, 2025.
  18. Multiple myeloma. National Comprehensive Cancer Network. https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1445. Accessed April 22, 2025.
  19. Shoushtari AN, et al. Principles of cancer immunotherapy. https://www.uptodate.com/contents/search. Accessed April 21, 2025.
  20. T-cell transfer therapy. National Cancer Institute. https://www.cancer.gov/about-cancer/treatment/types/immunotherapy/t-cell-transfer-therapy. Accessed April 24, 2025.
  21. Health Education & Content Services. Chimeric antigen receptor T-cell (CAR-T) therapy. Mayo Clinic; 2019.
  22. Bashir Q, et al., eds. Process and general management of patients undergoing chimeric antigen receptor therapies. In: Manual of Hematopoietic Cell Transplantation and Cellular Therapies. Elsevier; 2024. https://www.clinicalkey.com. Accessed May 1, 2025.
  23. Neelapu SS, et al. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. New England Journal of Medicine. 2017; doi:10.1056/NEJMoa1707447.

Related

News from Mayo Clinic

Products & Services